Ignite Creation Date:
2025-12-24 @ 5:24 PM
Ignite Modification Date:
2025-12-29 @ 10:21 PM
Study NCT ID:
NCT01855750
Status:
COMPLETED
Last Update Posted:
2025-02-04
First Post:
2013-05-14
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Sponsor:
Janssen Research & Development, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-09-03
Start Date Type:
ACTUAL
Primary Completion Date:
2018-02-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-04-05
Completion Date Type:
ACTUAL
First Submit Date:
2013-05-14
First Submit QC Date:
None
Study First Post Date:
2013-05-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-02-22
Results First Submit QC Date:
None
Results First Post Date:
2019-03-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-01-31
Last Update Post Date:
2025-02-04
Last Update Post Date Type:
ACTUAL